Search results

Search:
in the keywords: BCR-ABL ONCOGENE

Sort By:

Limit search:

Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene

100%

Baranska M., Lewandowski K., Gniot M., Iwola M., Lewandowska., Komarnicki M.

Journal of Applied Genetics

2008

vol. 49

issue 2

201-203

Point mutations of bcr-abl tyrosine kinase are the most frequent causes of imatinib resistance in chronic myeloid leukaemia (CML) patients. In most CML cases with BCR-ABL mutations leading to imatinib resistance the second generation of tyrosine kinase inhibitors (TKI- e.g. nilotinib or dasatinib) may be effective. Here, we report a case of a CML patient who during imatinib treatment did not obtain clinical and cytogenetic response within 12 months of therapy. The sequencing of BCR-ABL kinase domains was performed and revealed the presence of a F359I point mutation (TTC-to-ATC nucleotide change leading to Phe-to-Ile amino acid substitution). After 1 month of nilotinib therapy a rapid progression of clinical symptoms was observed. In the presence of the F359I point mutation only dasatinib treatment overcame imatinib and nilotinib resistance.

Refine search results

1 Journal of Applied Genetics

1 2008

1 Baranska M.

1 Gniot M.

1 Iwola M.

1 Komarnicki M.

1 Lewandowska.

1 Lewandowski K.

Search results

Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene